-
April 14, 2022 Why Investors Should Care About MindMed’s LSD Trial for AnxietyMindMed will present preliminary results from a Phase 2a study treating Generalized Anxiety Disorder with...
-
April 12, 2022 Numinus Acquiring Novamind in First Major Psychedelics MergerThis deal will make Numinus the psychedelic medicines company with the highest revenue, though of...
-
April 7, 2022 Mushrooms Have Their Own Language, New Study SuggestsThe electric pulses could be organized into “trains” that resemble human words, and a vocabulary...
-
March 31, 2022 How to Enroll in a Psychedelic Clinical Trial in 5 Easy StepsInterested in participating in a psychedelic study? Here's an in-depth walk through guide so you...
-
March 30, 2022 5 Most Important Psychedelic Clinical Trials in 2022Here's why we think MAPS’ second Phase 3 MDMA trial is the most important psychedelic...
-
March 24, 2022 Psilocybin Is Effective in Reducing Weight Gain, New Study ShowsNeonMind finds that its proprietary psilocybin has the ability to target visceral fat, effectively reducing...
-
March 23, 2022 Ketamine Study Suggests the Psychedelic Could Treat Parkinson’s DiseasePharmaTher evaluates safety, tolerability and efficacy of low-dose ketamine infusion for treatment of LID in...
-
March 21, 2022 Another Psychedelics Company Is CrashingCore One Labs appears to be following in footsteps of Mind Cure, but that doesn't...
-
March 18, 2022 Is Small Pharma a Good Psychedelic Stock Investment?Our resident Psychedelic Investor James Hallifax looks at the pros and cons of this Canadian-based...
-
March 17, 2022 Can Psychedelics like MDMA Cure Eating Disorders?Anyone who has ever suffered from an eating disorder, such as anorexia or bulimia, knows...
